For Q1 FY2026 (ended March 31, 2026), Aurinia reported revenue of $77.7 million, up 24.4% year-over-year. Net income was $34.4 million, a 47.2% increase, with diluted EPS of $0.25 (up 56.3%). Operating income rose 89.6% to $41.4 million. Cash stood at $40.7 million, and equity was $567.6 million.
•Revenue grew 24.4% YoY to $77.7 million.
•Net income increased 47.2% to $34.4 million.
•Diluted EPS rose 56.3% to $0.25.
•Operating income surged 89.6% to $41.4 million.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Aurinia Pharmaceuticals Inc., a biopharmaceutical company delivers therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis.
It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. Founded in 1993, the company is headquartered in Edmonton, Canada.
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases that have high unmet medical needs. Its primary marketed product is LUPKYNIS (voclosporin), an oral therapy approved for the treatment of adult patients with active lupus nephritis, a serious complication of systemic lupus erythematosus. The company also has a pipeline candidate, aritinercept, which is a dual inhibitor of B cell-activating factor and proliferation-inducing ligand, being developed for the potential treatment of autoimmune diseases. Aurinia operates in the United States and Japan, addressing conditions where current treatment options are limited.
Where is Aurinia Pharmaceuticals listed and what currency does it trade in?
Aurinia Pharmaceuticals Inc. is listed on the Nasdaq Global Market (NasdaqGM) under the ticker symbol AUPH. Its shares trade in US dollars (USD), reflecting its primary listing on a US-based exchange. The company is headquartered in Edmonton, Canada, but its stock is accessible to international investors through the Nasdaq, which is one of the world's largest stock exchanges. The use of USD as the trading currency means that investors outside the United States may need to consider foreign exchange implications when buying or selling shares.
What sector and industry does Aurinia Pharmaceuticals belong to?
Aurinia Pharmaceuticals operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on researching, developing, and commercializing therapies for autoimmune diseases. The biotechnology industry is characterized by high research and development costs, long product development cycles, and significant regulatory oversight. Aurinia's work in this field involves leveraging scientific innovation to create treatments that address unmet medical needs, such as its approved product LUPKYNIS for lupus nephritis. The company's position in the Healthcare sector underscores its commitment to improving patient outcomes through advanced therapeutic solutions.
Where is Aurinia Pharmaceuticals headquartered and what markets does it serve?
Aurinia Pharmaceuticals Inc. is headquartered in Edmonton, Canada, and was founded in 1993. The company primarily serves the United States and Japan, two major pharmaceutical markets with significant populations of patients suffering from autoimmune diseases. Its commercial focus is on delivering LUPKYNIS (voclosporin) to adult patients with active lupus nephritis in these regions. Additionally, Aurinia is developing aritinercept for potential use in other autoimmune conditions, which could expand its market reach. The company's Canadian base provides a strategic location for research and development, while its operations in the US and Japan allow it to tap into large healthcare systems with high demand for innovative therapies.
How does Aurinia Pharmaceuticals make money?
Aurinia Pharmaceuticals generates revenue primarily through the commercialization of its approved product, LUPKYNIS (voclosporin), an oral therapy for adult patients with active lupus nephritis. Lupus nephritis is a severe kidney inflammation caused by systemic lupus erythematosus, and LUPKYNIS is one of the few targeted treatments available for this condition. The company sells the drug in the United States and Japan, where it has established a commercial presence. In addition to product sales, Aurinia may earn revenue through licensing agreements or partnerships, though its primary focus remains on expanding LUPKYNIS adoption. The company also invests in research and development for pipeline candidates like aritinercept, which could become future revenue sources if approved.